Diabetes is very common in people living in post-acute and long-term environments, affecting 25% to 34% of these individuals.

IDF creating new Type 2 diabetes guidelines with global experts, focusing on patient-centered care and global accessibility.

Drugs for diabetic kidney disease treatment have greatly expanded, allowing research and consensus on their optimal use.

The study is the first set of global estimates directly linking diabetes prevalence with treatment coverage over a ...

Our 200+ faculty members from different schools and departments are dedicated to advancing the field of diabetes through cutting-edge research. In the ultimate search for a curative therapy for ...

Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).

“It’s clear from today’s discussion that an FDA-approved treatment and clear education on managing risk is urgently needed, and we believe our data supports this need,” said Dr Mike Exton, chief ...

These two competitors have made a habit of conducting clinical trials against each other, seeking to one-up the other’s latest diabetes treatment. This is obviously a welcome sight for the 35 ...